InspireMD Q2 net loss widens to $13.2M ($0.26/share); revenue up 2.3% to $1.78M

InspireMD, Inc.

2025-Q2 EPS reported -$0.48 revenue$3,307,000

Net loss of $13.2M ($0.26 per share) vs $7.9M loss ($0.22) in Q2 2024; operating expenses surged 55% to $13.3M.
Revenue of $1.78M, up 2.3% YoY; gross profit fell 5.4% to $313k; cash & securities dropped to $19.4M from $34.6M.
Company raised $58M in gross proceeds from equity private placement and warrant exercise.
FDA granted PMA approval for CGuard Prime carotid stent; US commercial launch commenced; CE Mark under MDR also received.
Appointed Mike Lawless as CFO and added Raymond W. Cohen to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.